Tybriva 140mg Capsule

Tybriva 140mg Capsule contains the active ingredient Ibrutinib. It is indicated for the treatment of blood cancers including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia, and marginal zone lymphoma (MZL). These are cancers of white blood cells called lymphocytes, which form part of the immune system. They differ from one another according to the location of cancer development, the type of lymphocytes involved, and other distinguishing characteristics. Tybriva 140mg Capsule is also used to treat chronic graft versus host disease (cGvHD) following failure of systemic therapy. During allogeneic stem cell transplantation, patients receive stem cells from a donor. GvHD occurs when donor cells attack the patient's cells as foreign entities. Before taking Tybriva 140mg Capsule, discuss with your doctor if you have bleeding disorders, infection, liver disease, heart disease, or intolerance to certain sugars. This medication is not recommended for children and adolescents. Inform your doctor if you have recently undergone or are scheduled for any surgical procedure. Your doctor may discontinue Tybriva 140mg Capsule in anticipation of any planned surgical or medical procedure. Use effective contraception during treatment and for at least one month after the final dose. Avoid consuming grapefruit or oranges in any form during treatment, as they may increase blood levels of this medication. Maintain adequate fluid intake to prevent dehydration. Inform your doctor if you experience persistent diarrhoea.

Tybriva 140mg Capsule is used in the treatment of Mantle cell lymphoma Chronic lymphocytic leukemia (Blood cancer) Small lymphocytic lymphoma Waldenstrom’s macroglobulinemia Chronic graft vs. host disease after failure of systemic therapy

The mechanism of action of Tybriva 140mg involves blocking a specific protein called Bruton's tyrosine kinase (BTK) which plays a key role in the survival and growth of cancer cells. By inhibiting BTK, Tybriva 140mg prevents the cancer cells from receiving the signals they need to grow and divide, leading to their eventual death.

Consume this medicine at the same time each day. While taking Tybriva 140mg do not consume grapefruit or orange in any form during the treatment. Drink plenty of fluid to prevent dehydration.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious Bleeding problems Infections Decrease in blood cell counts Heart problems High BP Secondary cancer Tumor lysis syndrome Severe allergic reactions Common Nausea, vomiting, diarrhea Tiredness Muscle and bone pain Rash and bruising Mouth sores Pneumonia Fever, chills Breathlessness Constipation Dizziness Body pain Swollen ankles and feet Increased creatinine levels in blood Heavier periods and blood in urine Blurred vision Weakness and numbness

Contact your doctor immediately if you experience bleeding, infection, shortness of breath, or chest discomfort. Report to your doctor if you have had a history of heart failure or hepatitis infection. It is not recommended to take this medicine before or after surgery as it causes a delay in wound healing. Discuss effective contraceptive options with your healthcare provider and use them during treatment and for a month after the last dose of Tybriva 140mg .